RE: Final overall survival: Fulvestrant 500mg vs 250mg in the randomized CONFIRM trial

  1. Martin, M.
  2. Boyer, J.
  3. Stuart, M.
  4. Di Leo, A.
Aldizkaria:
Journal of the National Cancer Institute

ISSN: 1460-2105 0027-8874

Argitalpen urtea: 2017

Alea: 109

Zenbakia: 3

Mota: Gutuna

DOI: 10.1093/JNCI/DJW234 GOOGLE SCHOLAR lock_openSarbide irekia editor